A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Study Summary

This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.

Conditions

Hypertrophic Cardiomyopathy

Interventions / Drugs

Mavacamten

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment685 participants

Primary Completion—

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-04-11 04:08:14.745452+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.